Ligand discovery is a central step for the development of new pharmaceutical agents.

In close collaboration with ETH Z├╝rich, we have developed breakthrough technologies for ligand discovery (e.g., DNAencoded chemical libraries) and in the field of chemical proteomics (e.g., in vivo biotinylation, MHC peptidome analysis).

The ability to discover ligands to pharmaceutical targets of interest can be used for many biomedical applications. Within the Philochem group, we mainly focus on ligand-based pharmacodelivery strategies.

The ability to characterize disease-associated targets and to perform MHC peptidome analysis paves the way to novel pharmaceutical applications.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy